Abera Bioscience

Abera Bioscience Equity

The The Equity of Abera Bioscience (ABERA.SL) as of Oct 16, 2026 is 19.29 M SEK. In the previous year, The Equity was 8.66 M SEK — a change of 122.80% (higher).

Equity

19.29 MSEK

YoY

122.80%

Last updated:

In 2025, Abera Bioscience's equity was 19.29 M SEK, a 122.80% increase from the 8.66 M SEK equity in the previous year.

The Abera Bioscience Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
397,000.00 SEK
Jan 1, 2019
4.07 M SEK
Jan 1, 2020
428,000.00 SEK
Jan 1, 2021
29.15 M SEK
Jan 1, 2022
16.78 M SEK
Jan 1, 2023
5.66 M SEK
Jan 1, 2024
8.66 M SEK
Jan 1, 2025
19.29 M SEK
The Abera Bioscience Equity history
YEAREquityYoY
19.29 MSEK+122.80%
8.66 MSEK+53.07%
5.66 MSEK-66.30%
16.78 MSEK-42.44%
29.15 MSEK+6,711.21%
428,000.00SEK-89.49%
4.07 MSEK+925.44%
397,000.00SEK-86.90%
3.03 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Abera Bioscience Stock analysis

What does Abera Bioscience do? Abera Bioscience AB is a biotechnology company based in Uppsala, Sweden, operating within the healthcare sector. The company focuses on the research and development of pharmaceutical products, particularly in the field of vaccine development. It utilizes a proprietary vaccine delivery platform to advance vaccine candidates toward late pre-clinical or early clinical stages. Abera Bioscience aims to identify licensing partners for further development of its vaccine candidates. The company's technology is primarily applied in the development of vaccines targeting pneumococci and immunooncology. Abera Bioscience has a small operational footprint, employing five full-time staff members. It completed its initial public offering (IPO) on February 24, 2021, and is listed under the ticker ABERA.SL with ISIN SE0015245097. The company's headquarters are located in Uppsala, and it operates primarily within the Nordic market. Its website is https://aberabio.com/. The company's activities are centered on advancing vaccine candidates through its platform technology, with an emphasis on strategic partnerships for subsequent development phases. Abera Bioscience is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Abera Bioscience's Equity

Abera Bioscience's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Abera Bioscience's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Abera Bioscience's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Abera Bioscience's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Abera Bioscience’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Abera Bioscience stock

The Equity of Abera Bioscience is 19.29 M SEK in 2025.

The Equity of Abera Bioscience changed from 8.66 M SEK to 19.29 M SEK, representing a 122.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Abera Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Equity's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Abera Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Abera Bioscience

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Abera Bioscience